Centessa Pharmaceuticals-adr (CNTA) Technical Analysis
$39.47▲0.1%
Market is closed - opens 7 PM, 27 Apr 2026
Insights
- Centessa Pharmaceuticals-adr is currently in a neutral trading position according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Centessa Pharmaceuticals-adr stock suggests that it is range bound and no decision can be made based on this information
- Based on analysis of the Moving Averages technical indicator, Centessa Pharmaceuticals-adr stock is in a uptrend ↗️
- Based on analysis of the Pivot Points, the current market trend for Centessa Pharmaceuticals-adr stock suggests that it is a good time to sell or bad time to initiate a fresh position
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 73.65 | Sell |
Stochastic | 42.19, 42.97 | Neutral |
Ultimate Oscillator | 58.21 | Neutral |
Stochastic Relative Strength Index | 0.0, 10.02 | Neutral |
Moving Average Convergence Divergence | 2.63, 2.97 | Sell |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 39.53 | Buy |
20 | 37.94 | Buy |
50 | 31.08 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 39.15 | Buy |
20 | 37.35 | Buy |
50 | 33.01 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 39.53 | Neutral |
20 | 39.22 | Neutral |
50 | 35.88 | Buy |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 40.29 | Sell |
20 | 41.06 | Buy |
50 | 37.64 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 39.47 | Sell |
20 | 41.29 | Buy |
50 | 40.85 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 39.61 |
Resistance L2 | 39.58 |
Resistance L1 | 39.52 |
Pivot Point | 39.49 |
Support L1 | 39.43 |
Support L2 | 39.4 |
Support L3 | 39.34 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.